Programmed cell death ligand 1 is known to be expressed not only on tumour cells but also on stromal and haematopoietic cells and recent preclinical studies have suggested that expression of PD‐L1 on host myeloid cells has a stronger impact on antitumour immunity than PD‐L1 present on tumour cells [34, 35, 36]. Here, CD274 is linked to neoplasm.